Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction

Journal of Cellular and Molecular Medicine

Juliana L. Carvalho³  Vinicius B. A. Braga⁴  Marcos B. Melo²  Ana Carolina D. A. Campos³  Maira S. Oliveira¹  Dawidson A. Gomes³  Anderson J. Ferreira⁴  Robson A. S. Santos² 

[1] Department of Clinical and Surgery, College of Veterinary Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil;Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil;Department of Biochemistry and Immunology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil;Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

关键词: adipose tissue stem cells;    mesenchymal stem cells;    myocardial infarction;    cell therapy;    connexin‐43;   

DOI  :  10.1111/jcmm.12036

来源: Wiley

【 摘 要 】

Abstract

Cardiovascular diseases are the number one cause of death globally and are projected to remain the single leading cause of death. Treatment options abounds, although efficacy is limited. Recent studies attribute discrete and ephemeral benefits to adult stem cell therapies, indicating the urge to improve stem cell based–therapy. In this study, we show that priming mesenchymal stem cells (MSC) towards cardiomyogenic lineage enhances their beneficial effects in vivo as treatment option for acute phase myocardial infarction. MSC were primed using cardiomyogenic media for 4 days, after which peak expression of key cardiomyogenic genes are reached and protein expression of Cx-43 and sarcomeric α-actinin are observed. MSC and primed MSC (pMSC) were characterized in vitro and used to treat infarcted rats immediately after left anterior descending (LAD) occlusion. Echocardiography analysis indicated that MSC-treated myocardium presented discrete improvement in function, but it also showed that pMSC treatment lead to superior beneficial results, compared with undifferentiated MSC. Seven days after cell injection, MSC and pMSC could still be detected in the myocardium. Connexin-43 expression was quantified through immunoblotting, and was superior in pMSC, indicating that this could be a possible explanation for the superior performance of pMSC therapy.

【 授权许可】

CC BY   
© 2013 The Authors Journal of Cellular and Molecular Medicine Published by Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.